XNASDRIO
Market cap26mUSD
Jan 17, Last price
0.69USD
1D
6.74%
1Q
-32.62%
Jan 2017
-78.65%
IPO
-99.71%
Name
DarioHealth Corp
Chart & Performance
P/E
—
P/S
1.31
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
89.19%
Rev. gr., 5y
22.45%
Revenues
20m
-26.41%
Net income
-59m
L-4.45%
CFO
-30m
L-36.51%
Earnings
Mar 26, 2025
Profile
DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems. It also provides smart glucose meters; bluetooth connected blood pressure cuff; digital scales; biofeedback sensor devices; and diabetes management programs, including lifestyle changes, healthy eating, advanced tracking, and live coaching. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 20,352 -26.41% | 27,656 34.82% | |||||||
Cost of revenue | 76,541 | 84,466 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (56,189) | (56,810) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 64 | 4 | |||||||
Tax Rate | |||||||||
NOPAT | (56,253) | (56,814) | |||||||
Net income | (59,427) -4.45% | (62,193) -18.98% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 1,614 | 38,154 | |||||||
BB yield | -3.31% | -37.72% | |||||||
| Debt | |||||||||
Debt current | 4,176 | 9,116 | |||||||
Long-term debt | 26,472 | 20,052 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 276 | 910 | |||||||
Net debt | (6,149) | (20,195) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (30,379) | (47,845) | |||||||
CAPEX | (584) | (573) | |||||||
Cash from investing activities | (547) | (573) | |||||||
Cash from financing activities | 18,253 | 61,940 | |||||||
FCF | (51,448) | (64,474) | |||||||
| Balance | |||||||||
Cash | 36,797 | 49,357 | |||||||
Long term investments | 6 | ||||||||
Excess cash | 35,779 | 47,980 | |||||||
Stockholders' equity | (349,358) | (285,847) | |||||||
Invested Capital | 437,430 | 394,804 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 28,372 | 23,635 | |||||||
Price | 1.72 -59.81% | 4.28 -67.00% | |||||||
Market cap | 48,800 -51.76% | 101,158 -52.99% | |||||||
EV | 42,651 | 80,963 | |||||||
EBITDA | (51,204) | (52,093) | |||||||
EV/EBITDA | |||||||||
Interest | 645 | 1,876 | |||||||
Interest/NOPBT | |||||||||